Erica Rinker, MD
Family Medicine · Sheridan, WYNPI 1679860597
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $446, 8.7 times the $51 reported in 2019.
Across 61 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$192
- Madrigal Pharmaceuticals$155
- AstraZeneca$134
- Lilly USA, LLC$96
- Amgen$90
- Novo Nordisk$76
- plus $415 from 14 others
What the payments were for
- Food & beverage$1,158100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $192 |
| Madrigal Pharmaceuticals | 3 | $155 |
| AstraZeneca | 9 | $134 |
| Lilly USA, LLC | 6 | $96 |
| Amgen | 6 | $90 |
| Novo Nordisk | 5 | $76 |
| Exact Sciences | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Merck | 2 | $30 |
| Boehringer Ingelheim | 1 | $24 |
| Medtronic | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Alkermes, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$120
How this compares
$1,158 in reported general payments places this provider in the 80th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $58,991 |
| EliquisApixaban | 37 | $42,493 |
| TrulicityDulaglutide | 19 | $19,454 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 11 | $14,572 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,852 |
| FarxigaDapagliflozin Propanediol | 13 | $12,469 |
| Oxcarbazepine | 13 | $5,377 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,671 |
| Pulmicort FlexhalerBudesonide | 11 | $2,412 |
| Pantoprazole Sodium | 132 | $1,877 |
| Estradiol | 37 | $1,775 |
| Levothyroxine Sodium | 206 | $1,690 |
| DottiEstradiol | 12 | $1,556 |
| Gabapentin | 70 | $1,363 |
| Atorvastatin Calcium | 174 | $1,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $76 | $73,56370 claims |
| PfizerEliquis | $11 | $42,49337 claims |
| Lilly USA, LLCTrulicity | $96 | $19,45419 claims |
| AstraZenecaFarxiga, Pulmicort Flexhaler | $134 | $14,88124 claims |
| GSKTrelegy Ellipta | $192 | $13,85212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Sheridan
- Emily DenneySheridan$1K
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Jonathon MedinaCheyenne$6K
- Carol FischerCheyenne$6K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
- Jacob JohnsonRock Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.